Targeting the SARS-CoV-2 HR1 with Small Molecules as Inhibitors of the Fusion Process.
Ontology highlight
ABSTRACT: The rapid and global propagation of the novel human coronavirus that causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of this virus. In this paper, we studied the spike protein S2 domain of SARS-CoV-2 as it is the most conserved component and controls the crucial fusion process of SARS-CoV-2 as a target for different databases of small organic compounds. Our in silico methodology, based on pharmacophore modeling, docking simulation and molecular dynamics simulations, was first validated with ADS-J1, a potent small-molecule HIV fusion inhibitor that has already proved effective in binding the HR1 domain and inhibiting the fusion core of SARS-CoV-1. It then focused on finding novel small mole
SUBMITTER: Gentile D
PROVIDER: S-EPMC9456533 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA